Multi-Omics Disease Characterization Pipeline
Characterize diseases across multiple molecular layers (genomics, transcriptomics, proteomics, pathways) to provide systems-level understanding of disease mechanisms, identify therapeutic opportunities, and discover biomarker candidates.
KEY PRINCIPLES:
- Report-first approach - Create report file FIRST, then populate progressively
- Disease disambiguation FIRST - Resolve all identifiers before omics analysis
- Layer-by-layer analysis - Systematically cover all omics layers
- Cross-layer integration - Identify genes/targets appearing in multiple layers
- Evidence grading - Grade all evidence as T1 (human/clinical) to T4 (computational)
- Tissue context - Emphasize disease-relevant tissues/organs
- Quantitative scoring - Multi-Omics Confidence Score (0-100)
- Druggable focus - Prioritize targets with therapeutic potential
- Biomarker identification - Highlight diagnostic/prognostic markers
- Mechanistic synthesis - Generate testable hypotheses
- Source references - Every statement must cite tool/database
- Completeness checklist - Mandatory section showing analysis coverage
- English-first queries - Always use English terms in tool calls. Respond in user's language
Multi-omics disease characterization asks: what molecular layers are dysregulated? Genomic mutations → transcriptomic changes → proteomic effects → metabolomic consequences. Concordance across layers strengthens the finding. Discordance reveals regulatory complexity.
LOOK UP, DON'T GUESS
When uncertain about any scientific fact, SEARCH databases first rather than reasoning from memory. A database-verified answer is always more reliable than a guess.
COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
When to Use This Skill
Apply when users:
- Ask about disease mechanisms across omics layers
- Need multi-omics characterization of a disease
- Want to understand disease at the systems biology level
- Ask "What pathways/genes/proteins are involved in [disease]?"
- Need biomarker discovery for a disease
- Want to identify druggable targets from disease profiling
- Ask for integrated genomics + transcriptomics + proteomics analysis
- Need cross-layer concordance analysis
- Ask about disease network biology / hub genes
NOT for (use other skills instead):
- Single gene/target validation -> Use
tooluniverse-drug-target-validation
- Drug safety profiling -> Use
tooluniverse-adverse-event-detection
- General disease overview -> Use
tooluniverse-disease-research
- Variant interpretation -> Use
tooluniverse-variant-interpretation
- GWAS-specific analysis -> Use
tooluniverse-gwas-* skills
- Pathway-only analysis -> Use
tooluniverse-systems-biology
Input Parameters
| Parameter |
Required |
Description |
Example |
| disease |
Yes |
Disease name, OMIM ID, EFO ID, or MONDO ID |
Alzheimer disease, MONDO_0004975 |
| tissue |
No |
Tissue/organ of interest |
brain, liver, blood |
| focus_layers |
No |
Specific omics layers to emphasize |
genomics, transcriptomics, pathways |
Pipeline Overview
The pipeline runs 9 phases sequentially. Each phase uses specific tools documented in detail in tool-reference.md.
Phase 0: Disease Disambiguation (ALWAYS FIRST)
Resolve disease to standard identifiers (MONDO/EFO) for all downstream queries.
- Primary tool:
OpenTargets_get_disease_id_description_by_name
- Get description, synonyms, therapeutic areas, disease hierarchy, cross-references
- CRITICAL: Disease IDs use underscore format (e.g.,
MONDO_0004975), NOT colon
- If ambiguous, present top 3-5 options and ask user to select
Phase 1: Genomics Layer
Identify genetic variants, GWAS associations, and genetically implicated genes.
- Tools:
gwas_search_associations (use efo_id for precision, not free-text disease_trait), gwas_get_snps_for_gene, ClinVar, OpenTargets associated targets
gnomad_get_gene_constraints — gene constraint metrics (pLI, oe_lof) to interpret whether LoF variants are tolerated vs. haploinsufficient
- Get top 10-15 genes with genetic evidence scores; track Ensembl IDs for downstream phases
Phase 2: Transcriptomics Layer
Identify differentially expressed genes, tissue-specific expression, and expression-based biomarkers.
GTEx_get_expression_summary — baseline expression across 54 tissues (accepts gene_symbol directly)
- Tools: Expression Atlas, HPA (tissue expression), EuropePMC scores
- Check expression in disease-relevant tissues for top genes from Phase 1
Phase 3: Proteomics & Interaction Layer
Map protein-protein interactions, identify hub genes, and characterize interaction networks.
UniProt_get_function_by_accession — protein function narrative (essential for mechanistic context)
- Tools:
STRING_get_network (param: identifiers, species=9606), intact_get_interactions, HumanBase
- Build PPI network from top 15-20 genes; identify hub genes by degree centrality
Phase 4: Pathway & Network Layer
Identify enriched biological pathways and cross-pathway connections.
ReactomeAnalysis_pathway_enrichment — identifiers are newline-separated (\n), NOT space-separated
enrichr_gene_enrichment_analysis — param: gene_list (array), libs (array). NOTE: data field is a JSON string that needs parsing
kegg_search_pathway — pathway keyword search
Phase 5: Gene Ontology & Functional Annotation
Characterize biological processes, molecular functions, and cellular components.
- Tools: Enrichr (GO libraries), QuickGO, GO annotations, OpenTargets GO
- Run GO enrichment for all 3 aspects (BP, MF, CC)
Phase 6: Therapeutic Landscape
Map approved drugs, druggable targets, repurposing opportunities, and clinical trials.
DGIdb_get_drug_gene_interactions — drug interactions by gene (param: genes as array). Often more comprehensive than OpenTargets for drug-gene data.
- OpenTargets drugs/tractability (use EFO IDs like
EFO_0000384 for Crohn's, not MONDO — MONDO IDs may return null for drug queries)
search_clinical_trials — query_term is REQUIRED
Phase 7: Multi-Omics Integration
Integrate findings across all layers. See integration-scoring.md for full details.
- Cross-layer gene concordance: count layers per gene, score multi-layer hub genes
- Direction concordance: genetics + expression agreement
- Biomarker identification: diagnostic, prognostic, predictive
- Mechanistic hypothesis generation
Phase 8: Report Finalization
Write executive summary, calculate confidence score, verify completeness.
- See
integration-scoring.md for quality checklist and scoring formula
Key Tool Parameter Notes
These are the most common parameter pitfalls:
OpenTargets disease IDs: underscore format (MONDO_0004975), NOT colon
STRING protein_ids: must be array (['APOE']), not string
enrichr libs: must be array (['KEGG_2021_Human'])
HPA_get_rna_expression_by_source: ALL 3 params required (gene_name, source_type, source_name)
humanbase_ppi_analysis: ALL params required (gene_list, tissue, max_node, interaction, string_mode)
expression_atlas_disease_target_score: pageSize is REQUIRED
search_clinical_trials: query_term is REQUIRED even if condition is provided
For full tool parameters and per-phase workflows, see tool-reference.md.
Reference Files
All detailed content is in reference files in this directory:
| File |
Contents |
tool-reference.md |
Full tool parameters, inputs/outputs, per-phase workflows, quick reference table |
report-template.md |
Complete report markdown template with all sections and checklists |
integration-scoring.md |
Confidence score formula (0-100), evidence grading (T1-T4), integration procedures, quality checklist |
response-formats.md |
Verified JSON response structures for key tools |
use-patterns.md |
Common use patterns, edge case handling, fallback strategies |
1---2name: tooluniverse-multiomic-disease-characterization3description: Comprehensive disease characterization across genomics, transcriptomics, proteomics, and pathways for systems-level understanding. Identifies therapeutic opportunities and biomarker candidates by integrating multi-layer molecular data. Use for full-omics disease deep-dive reports, mechanism mapping, and biomarker-and-target identification from multi-omics data.4---5
6# Multi-Omics Disease Characterization Pipeline
7
8Characterize diseases across multiple molecular layers (genomics, transcriptomics, proteomics, pathways) to provide systems-level understanding of disease mechanisms, identify therapeutic opportunities, and discover biomarker candidates.
9
10**KEY PRINCIPLES**:
111. **Report-first approach** - Create report file FIRST, then populate progressively
122. **Disease disambiguation FIRST** - Resolve all identifiers before omics analysis
133. **Layer-by-layer analysis** - Systematically cover all omics layers
144. **Cross-layer integration** - Identify genes/targets appearing in multiple layers
155. **Evidence grading** - Grade all evidence as T1 (human/clinical) to T4 (computational)
166. **Tissue context** - Emphasize disease-relevant tissues/organs
177. **Quantitative scoring** - Multi-Omics Confidence Score (0-100)
188. **Druggable focus** - Prioritize targets with therapeutic potential
199. **Biomarker identification** - Highlight diagnostic/prognostic markers
2010. **Mechanistic synthesis** - Generate testable hypotheses
2111. **Source references** - Every statement must cite tool/database
2212. **Completeness checklist** - Mandatory section showing analysis coverage
2313. **English-first queries** - Always use English terms in tool calls. Respond in user's language
24
25Multi-omics disease characterization asks: what molecular layers are dysregulated? Genomic mutations → transcriptomic changes → proteomic effects → metabolomic consequences. Concordance across layers strengthens the finding. Discordance reveals regulatory complexity.
26
27## LOOK UP, DON'T GUESS
28When uncertain about any scientific fact, SEARCH databases first rather than reasoning from memory. A database-verified answer is always more reliable than a guess.
29
30---
31
32## COMPUTE, DON'T DESCRIBE
33When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
34
35## When to Use This Skill
36
37Apply when users:
38- Ask about disease mechanisms across omics layers
39- Need multi-omics characterization of a disease
40- Want to understand disease at the systems biology level
41- Ask "What pathways/genes/proteins are involved in [disease]?"
42- Need biomarker discovery for a disease
43- Want to identify druggable targets from disease profiling
44- Ask for integrated genomics + transcriptomics + proteomics analysis
45- Need cross-layer concordance analysis
46- Ask about disease network biology / hub genes
47
48**NOT for** (use other skills instead):
49- Single gene/target validation -> Use `tooluniverse-drug-target-validation`
50- Drug safety profiling -> Use `tooluniverse-adverse-event-detection`
51- General disease overview -> Use `tooluniverse-disease-research`
52- Variant interpretation -> Use `tooluniverse-variant-interpretation`
53- GWAS-specific analysis -> Use `tooluniverse-gwas-*` skills
54- Pathway-only analysis -> Use `tooluniverse-systems-biology`
55
56---
57
58## Input Parameters
59
60| Parameter | Required | Description | Example |
61|-----------|----------|-------------|---------|
62| **disease** | Yes | Disease name, OMIM ID, EFO ID, or MONDO ID | `Alzheimer disease`, `MONDO_0004975` |
63| **tissue** | No | Tissue/organ of interest | `brain`, `liver`, `blood` |
64| **focus_layers** | No | Specific omics layers to emphasize | `genomics`, `transcriptomics`, `pathways` |
65
66---
67
68## Pipeline Overview
69
70The pipeline runs 9 phases sequentially. Each phase uses specific tools documented in detail in `tool-reference.md`.
71
72### Phase 0: Disease Disambiguation (ALWAYS FIRST)
73Resolve disease to standard identifiers (MONDO/EFO) for all downstream queries.
74- Primary tool: `OpenTargets_get_disease_id_description_by_name`
75- Get description, synonyms, therapeutic areas, disease hierarchy, cross-references
76- **CRITICAL**: Disease IDs use underscore format (e.g., `MONDO_0004975`), NOT colon
77- If ambiguous, present top 3-5 options and ask user to select
78
79### Phase 1: Genomics Layer
80Identify genetic variants, GWAS associations, and genetically implicated genes.
81- Tools: `gwas_search_associations` (use `efo_id` for precision, not free-text `disease_trait`), `gwas_get_snps_for_gene`, ClinVar, OpenTargets associated targets
82- `gnomad_get_gene_constraints` — gene constraint metrics (pLI, oe_lof) to interpret whether LoF variants are tolerated vs. haploinsufficient
83- Get top 10-15 genes with genetic evidence scores; track Ensembl IDs for downstream phases
84
85### Phase 2: Transcriptomics Layer
86Identify differentially expressed genes, tissue-specific expression, and expression-based biomarkers.
87- `GTEx_get_expression_summary` — baseline expression across 54 tissues (accepts `gene_symbol` directly)
88- Tools: Expression Atlas, HPA (tissue expression), EuropePMC scores
89- Check expression in disease-relevant tissues for top genes from Phase 1
90
91### Phase 3: Proteomics & Interaction Layer
92Map protein-protein interactions, identify hub genes, and characterize interaction networks.
93- `UniProt_get_function_by_accession` — protein function narrative (essential for mechanistic context)
94- Tools: `STRING_get_network` (param: `identifiers`, `species`=9606), `intact_get_interactions`, HumanBase
95- Build PPI network from top 15-20 genes; identify hub genes by degree centrality
96
97### Phase 4: Pathway & Network Layer
98Identify enriched biological pathways and cross-pathway connections.
99- `ReactomeAnalysis_pathway_enrichment` — identifiers are **newline-separated** (`\n`), NOT space-separated
100- `enrichr_gene_enrichment_analysis` — param: `gene_list` (array), `libs` (array). NOTE: `data` field is a JSON string that needs parsing
101- `kegg_search_pathway` — pathway keyword search
102
103### Phase 5: Gene Ontology & Functional Annotation
104Characterize biological processes, molecular functions, and cellular components.
105- Tools: Enrichr (GO libraries), QuickGO, GO annotations, OpenTargets GO
106- Run GO enrichment for all 3 aspects (BP, MF, CC)
107
108### Phase 6: Therapeutic Landscape
109Map approved drugs, druggable targets, repurposing opportunities, and clinical trials.
110- `DGIdb_get_drug_gene_interactions` — drug interactions by gene (param: `genes` as array). Often more comprehensive than OpenTargets for drug-gene data.
111- OpenTargets drugs/tractability (use **EFO IDs** like `EFO_0000384` for Crohn's, not MONDO — MONDO IDs may return null for drug queries)
112- `search_clinical_trials` — `query_term` is REQUIRED
113
114### Phase 7: Multi-Omics Integration
115Integrate findings across all layers. See `integration-scoring.md` for full details.
116- Cross-layer gene concordance: count layers per gene, score multi-layer hub genes
117- Direction concordance: genetics + expression agreement
118- Biomarker identification: diagnostic, prognostic, predictive
119- Mechanistic hypothesis generation
120
121### Phase 8: Report Finalization
122Write executive summary, calculate confidence score, verify completeness.
123- See `integration-scoring.md` for quality checklist and scoring formula
124
125---
126
127## Key Tool Parameter Notes
128
129These are the most common parameter pitfalls:
130- `OpenTargets` disease IDs: underscore format (`MONDO_0004975`), NOT colon
131- `STRING` `protein_ids`: must be **array** (`['APOE']`), not string
132- `enrichr` `libs`: must be **array** (`['KEGG_2021_Human']`)
133- `HPA_get_rna_expression_by_source`: ALL 3 params required (`gene_name`, `source_type`, `source_name`)
134- `humanbase_ppi_analysis`: ALL params required (`gene_list`, `tissue`, `max_node`, `interaction`, `string_mode`)
135- `expression_atlas_disease_target_score`: `pageSize` is REQUIRED
136- `search_clinical_trials`: `query_term` is REQUIRED even if `condition` is provided
137
138For full tool parameters and per-phase workflows, see `tool-reference.md`.
139
140---
141
142## Reference Files
143
144All detailed content is in reference files in this directory:
145
146| File | Contents |
147|------|----------|
148| `tool-reference.md` | Full tool parameters, inputs/outputs, per-phase workflows, quick reference table |
149| `report-template.md` | Complete report markdown template with all sections and checklists |
150| `integration-scoring.md` | Confidence score formula (0-100), evidence grading (T1-T4), integration procedures, quality checklist |
151| `response-formats.md` | Verified JSON response structures for key tools |
152| `use-patterns.md` | Common use patterns, edge case handling, fallback strategies |